Also trades as: NRX.V (TSXV) · $vol 0M
NRXBF OTC
NurExone Biologic Inc.
1W: +4.4%
1M: +6.5%
3M: +14.8%
YTD: +19.1%
$0.45
+0.00 (+1.02%)
Weekly Expected Move ±10.4%
$0
$0
$0
$0
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$32.7M
52W Range0.3002-0.706
Volume900
Avg Volume7,850
Beta0.39
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOLior Shaltiel
Employees16
SectorHealthcare
IndustryBiotechnology
IPO Date2023-11-10
Websitenurexone.com
1 Adelaide Street East
Toronto, ON M5C 2V9
CA
Toronto, ON M5C 2V9
CA
About NurExone Biologic Inc.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.
Latest News
NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
Recent Insider Trades
No insider trades found